Cilostazol for Prevention of Recurrent Stroke Trial
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2000 participants.
Also called NCT07174414
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 2,000 participants
- Sponsor
- Registry
-
NCT07174414
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT07174414. Randomized; quadruple masking; primary purpose prevention. Start 2026-10-15 (actual); primary completion 2031-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cilostazol for Prevention of Recurrent Stroke Trial
- Acronym
- Clarity
- Condition
- Stroke Recurrence
- Condition
- Myocardial Infarction
- Condition
- Vascular Death
- Condition
- Ischemic Stroke
- Condition
- Stroke (CVA) or Transient Ischemic Attack
- Condition
- Recurrent Stroke
- Intervention (Drug)
- Cilostazol 100 mg Tablets
- Intervention (Drug)
- Placebo
- Lead sponsor
- Stanford University
- Collaborator
- National Institute of Neurological Disorders and Stroke (NINDS)
- Collaborator
- Yale University
- Collaborator
- University of Cincinnati
- Collaborator
- Medical University of South Carolina
Record details
- Record id
cardio:ct-nct07174414- Content hash
94f0d10e3d91e35b4273f134cf2ce03e8adcda58218cfd3fd2017b924d042641